Business
    Next Score View the next score

    Mass. Movers

    Harvard Bioscience will spin off subsidiary

    Harvard Bioscience aims to raise $20 million in an IPO.
    istockphoto.com
    Harvard Bioscience aims to raise $20 million in an IPO.
    Advertisement

    Harvard Bioscience Inc. said it will spin off its regenerative medicine device business through an IPO next year. The Holliston company will seek to raise $20 million by taking public its subsidiary, Harvard Apparatus Regenerative Technology, which is developing parts for “bioartificial” organs such as replacement tracheas. CEO Chane Graziano said it has become too complicated to manage the research tool business and clinical-stage regenerative device unit together.